financetom
Business
financetom
/
Business
/
Conduent to Work With Microsoft on Generative AI Solutions; Shares Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Conduent to Work With Microsoft on Generative AI Solutions; Shares Rise
Apr 29, 2024 7:48 AM

10:17 AM EDT, 04/29/2024 (MT Newswires) -- Conduent ( CNDT ) said Monday it will use the Microsoft ( MSFT ) Azure OpenAI service to help accelerate cycle times for Conduent's ( CNDT ) global clients through the use of generative artificial intelligence.

The collaboration is initially exploring generative AI implementation in healthcare claims management, customer service platforms and fraud detection, with three pilots in progress, the company said.

Conduent ( CNDT ) shares were up 3.6% in recent trading, while Microsoft ( MSFT ) fell 1.2%.

Price: 3.17, Change: +0.11, Percent Change: +3.59

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients
Jun 26, 2025
08:16 AM EDT, 06/26/2025 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Thursday it was able to identify a patient selection biomarker in its exploratory phase 2 proof-of-concept trial of ALTO-203 in major depressive disorder patients with elevated levels of anhedonia. ALTO-203 demonstrated clear effects on objective measures of attention and wakefulness, in the phase 2 trial, the company...
BRIEF-Hope Therapeutics and NRx Pharmaceuticals to Acquire Interest in Cohen and Associates for Psychiatry Clinics
BRIEF-Hope Therapeutics and NRx Pharmaceuticals to Acquire Interest in Cohen and Associates for Psychiatry Clinics
Jun 26, 2025
June 26 (Reuters) - NRX Pharmaceuticals Inc ( NRXP ): * HOPE THERAPEUTICS, INC. AND NRX PHARMACEUTICALS, INC. ( NRXP ) ANNOUNCE AGREEMENT TO ACQUIRE INTEREST IN COHEN AND ASSOCIATES, LLC FOR HOPE'S NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS * NRX PHARMACEUTICALS INC ( NRXP ) - HOPE TO PURCHASE 49% INTEREST IN COHEN AND ASSOCIATES * NRX PHARMACEUTICALS INC (...
Hapbee to Raise $1.5 Million in Private Placement
Hapbee to Raise $1.5 Million in Private Placement
Jun 26, 2025
08:19 AM EDT, 06/26/2025 (MT Newswires) -- Hapbee Technologies ( HAPBF ) , which gained 18% on Wednesday, overnight, announced a non-brokered private placement consisting of up to 15.1 million units at $0.10 apiece for $1.5 million. The company also appointed Ahsan Ashraf as its new chief technology officer. Each Unit will consist of one subordinate voting common share and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved